Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Conditions
Brief summary
This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either pemetrexed (non-squamous disease) or gemcitabine (squamous disease) in programmed death-ligand 1 (PD-L1)-selected, chemotherapy-naive participants with Stage IV Non-Squamous or Squamous NSCLC.
Interventions
Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
DRUGCarboplatin
Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.
DRUGCisplatin
Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m\^2) every 21 days for 4 or 6 cycles as per local standard of care.
DRUGGemcitabine
Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m\^2 (in combination with cisplatin) or 1000 mg/m\^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.
DRUGPemetrexed
Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m\^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC * No prior treatment for Stage IV non-squamous or squamous NSCLC. Participant known to have a sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) fusion oncogene are excluded from the study * Tumor PD-L1 expression as determined by immunohistochemistry (IHC) assay of archival tumor tissue or tissue obtained at screening * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 * Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) * Adequate hematologic and end-organ function
Exclusion criteria
* Known sensitizing mutation in the EGFR gene or ALK fusion oncogene * Active or untreated central nervous system (CNS) metastases as determined by Computed Tomography (CT) or magnetic resonance imaging (MRI) evaluation * Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome * Pregnant or lactating women * History of autoimmune disease * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted * Positive test for Human Immunodeficiency Virus (HIV) * Active hepatitis B or hepatitis C * Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, anti PD1, and anti-PD-L1 therapeutic antibody * Severe infection within 4 weeks prior to randomization * Significant history of cardiovascular disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) in the TC3 or IC3-WT Populations | From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months) | OS is defined as the time from randomization to death from any cause. |
| Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | From randomization to death from any cause until data cut-off on 4 February 2020 (up to approximately 54.5 months) | OS is defined as the time from randomization to death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months) | PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested. |
| Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 4 Feb 2020 (up to approximately 54.5 months) | Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1. |
| Duration of Response (DOR) in the TC3 or IC3-WT Populations | From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. |
| Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months) | DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. |
| Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations | Baseline to 1 year or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | — |
| Percentage of Participants Who Are Alive at 2 Years in the TC3 or IC3-WT Populations | Baseline to 2 years or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | — |
| Percentage of Participants Who Are Alive at 1 Year in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Baseline to 1 year or death, whichever occurs first until clinical cut-off date on 4 February 2020 (up to approximately 54.5 months) | — |
| Percentage of Participants Who Are Alive at 2 Years in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Baseline to 2 years or death, whichever occurs first until clinical cut-off date on 4 February 2020 (up to approximately 54.5 months) | — |
| Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations | Baseline until data cut-off on 10 September 2018 (up to approximately 38 months) | TTD in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant. |
| Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations | Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 10 Sep 2018 (up to approximately 38 months) | Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1. |
| TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations | Baseline until data cut-off on 10 September 2018 (up to approximately 38 months) | TTD in patient-reported lung cancer symptoms, defined as time from randomization to deterioration (10-point change) in any of the following symptom subscales (cough, dyspnea \[multi-item scale\], and chest pain), whichever occurs first, as measured by the EORTC QLQ-LC13. EORTC QLQ-LC13 module incorporates one multi-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. |
| OS in Participants With PD-L1 Expression | From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months) | OS is defined as the time from randomization to death from any cause. |
| Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1 | From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | Investigator-assessed PFS according to RECIST v1.1 in the PD-L1 (defined with SP263 IHC assay) |
| OS in Participants With Blood Tumor Mutational Burden (bTMB) | From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months) | OS is defined as the time from randomization to death from any cause. |
| Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1 | From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | PFS according to RECIST v1.1 in the bTMB subpopulations. |
| Minimum Observed Serum Concentration (Cmin) of Atezolizumab | Prior to infusion (0 hour) on Day 1 of Cycles 2, 3, 4, 8, 16, and every eighth cycle thereafter, and at treatment discontinuation until data cut-off on 10 September 2018 (up to approximately 38 months) (cycle duration = 21 days) | — |
| Maximum Observed Serum Concentration (Cmax) of Atezolizumab | 0 hour (predose) and 30 minutes after atezolizumab infusion on Day 1 (infusion duration = up to 1 hour) | — |
| Percentage of Participants With at Least One Adverse Event | Baseline up to until data cut-off on 8 March 2022 (up to approximately 79.5 months) | Percentage of participants with at least one adverse event. |
| Percentage of Participants With Anti-therapeutic Antibodies (ATAs) | Baseline until data cut-off on 10 September 2018 (up to approximately 38 months) | — |
| Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Baseline until data cut-off on 10 September 2018 (up to approximately 38 months) | Change from baseline in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant. |
| Progression-free Survival (PFS) in the TC3 or IC3-WT Populations | From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested. |
Countries
Brazil, China, France, Germany, Greece, Hungary, Italy, Japan, Poland, Romania, Russia, Serbia, South Korea, Spain, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States
Participant flow
Recruitment details
Recruitment included: Japan (16 centers), Spain (15 centers), Greece (12 centers), Italy (12 centers), Brazil (11 centers), Russian (11 centers), France (10 centers), United States of America (9 centers), Ukraine (8 centers), Romania (7 centers), Turkey (6 centers), Poland (5 centers), Serbia (5 centers), Hungary (4 centers), Thailand (4 centers), Great Britain (3 centers), Republic of Korea (3 centers), Germany (2 centers), China (1 center).
Pre-assignment details
Study is considered 'Completed' because all of the criteria for End of Study have been met. Participants in survival follow-up completed their last visit and participants on active treatment were rolled over to a rollover study to continue their treatment.
Participants by arm
| Arm | Count |
|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months). | 287 |
| Atezolizumab Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months). | 285 |
| Total | 572 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 211 | 201 |
| Overall Study | Local ethics requires subjects' data be removed from aug 2020 to currently. | 0 | 1 |
| Overall Study | Lost to Follow-up | 3 | 5 |
| Overall Study | Participant Moved Into Roll-Over Study | 0 | 2 |
| Overall Study | Sponsor Decision | 1 | 0 |
| Overall Study | Study Terminated By Sponsor | 48 | 59 |
| Overall Study | Withdrawal by Subject | 24 | 17 |
Baseline characteristics
| Characteristic | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Atezolizumab | Total |
|---|---|---|---|
| Age, Continuous | 63.8 Years STANDARD_DEVIATION 8.8 | 63.1 Years STANDARD_DEVIATION 8.8 | 63.4 Years STANDARD_DEVIATION 8.8 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 14 Participants | 21 Participants | 35 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 265 Participants | 262 Participants | 527 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 8 Participants | 2 Participants | 10 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 33 Participants | 48 Participants | 81 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 2 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants | 2 Participants | 7 Participants |
| Race (NIH/OMB) White | 247 Participants | 232 Participants | 479 Participants |
| Sex: Female, Male Female | 89 Participants | 87 Participants | 176 Participants |
| Sex: Female, Male Male | 198 Participants | 198 Participants | 396 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 211 / 287 | 201 / 285 |
| other Total, other adverse events | 230 / 263 | 238 / 286 |
| serious Total, serious adverse events | 77 / 263 | 97 / 286 |
Outcome results
Primary
Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
OS is defined as the time from randomization to death from any cause.
Time frame: From randomization to death from any cause until data cut-off on 4 February 2020 (up to approximately 54.5 months)
Population: Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC2/3 or IC2/3-WT Population | 16.1 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC1/2/3 or IC1/2/3-WT Population | 14.7 Months |
| Atezolizumab | Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC2/3 or IC2/3-WT Population | 19.9 Months |
| Atezolizumab | Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC1/2/3 or IC1/2/3-WT Population | 18.9 Months |
Comparison: TC2/3 or IC2/3-WT Populationp-value: 0.309195% CI: [0.661, 1.14]Log Rank
Comparison: TC1/2/3 or IC/1/2/3-WTp-value: 0.10795% CI: [0.688, 1.037]Log Rank
Primary
Overall Survival (OS) in the TC3 or IC3-WT Populations
OS is defined as the time from randomization to death from any cause.
Time frame: From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Overall Survival (OS) in the TC3 or IC3-WT Populations | 13.1 Months |
| Atezolizumab | Overall Survival (OS) in the TC3 or IC3-WT Populations | 20.2 Months |
Comparison: TC3 or IC3-WT Populationp-value: 0.010695% CI: [0.398, 0.89]Log Rank
Secondary
Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations
Change from baseline in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant.
Time frame: Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for the TC3 or IC3-WT Populations.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 35 | -0.14 Score on a scale | Standard Deviation 0.95 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 43 | 0.40 Score on a scale | Standard Deviation 0.57 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 31 | 0.18 Score on a scale | Standard Deviation 1.72 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 33 | 0.00 Score on a scale | Standard Deviation 1.44 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 47 | 0.30 Score on a scale | Standard Deviation 0.68 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 49 | 1.40 Score on a scale | Standard Deviation 1.2 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 4 | 0.15 Score on a scale | Standard Deviation 1.21 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 6 | 0.30 Score on a scale | Standard Deviation 1.26 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 9 | 0.27 Score on a scale | Standard Deviation 1 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 10 | 0.30 Score on a scale | Standard Deviation 1.13 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 11 | 0.26 Score on a scale | Standard Deviation 1.32 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 12 | 0.22 Score on a scale | Standard Deviation 1.33 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 33 | 0.20 Score on a scale | Standard Deviation 0.78 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 34 | 0.16 Score on a scale | Standard Deviation 0.79 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 35 | 0.11 Score on a scale | Standard Deviation 0.58 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 15 | 0.10 Score on a scale | Standard Deviation 1.23 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 36 | 0.11 Score on a scale | Standard Deviation 0.86 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 16 | 0.00 Score on a scale | Standard Deviation 1.2 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 37 | 0.28 Score on a scale | Standard Deviation 0.63 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 38 | 0.40 Score on a scale | Standard Deviation 0.76 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 39 | 0.27 Score on a scale | Standard Deviation 0.81 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 17 | 0.22 Score on a scale | Standard Deviation 1.41 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 18 | 0.11 Score on a scale | Standard Deviation 1.26 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 22 | 0.30 Score on a scale | Standard Deviation 1.35 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 41 | 0.31 Score on a scale | Standard Deviation 0.58 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 27 | 0.05 Score on a scale | Standard Deviation 1.15 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 30 | 0.21 Score on a scale | Standard Deviation 1.45 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 52 | 1.10 Score on a scale | Standard Deviation 1.01 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 53 | 0.76 Score on a scale | Standard Deviation 1.28 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 54 | 1.10 Score on a scale | Standard Deviation 1.16 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 55 | 1.00 Score on a scale | Standard Deviation 0.53 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 56 | 0.40 Score on a scale | Standard Deviation 0.86 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 57 | 0.53 Score on a scale | Standard Deviation 0.61 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 58 | 0.80 Score on a scale | Standard Deviation 0.53 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 38 | 0.23 Score on a scale | Standard Deviation 0.72 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 39 | 0.22 Score on a scale | Standard Deviation 1 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 40 | 0.43 Score on a scale | Standard Deviation 1.02 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 59 | 0.60 Score on a scale | Standard Deviation 0.72 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 46 | 0.30 Score on a scale | Standard Deviation 0.45 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 67 | 0.50 Score on a scale | Standard Deviation 0.14 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 47 | 0.50 Score on a scale | Standard Deviation 0.71 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 68 | 0.20 Score on a scale | Standard Deviation 0.28 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 69 | 0.30 Score on a scale | Standard Deviation 0.42 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 48 | 0.50 Score on a scale | Standard Deviation 0.5 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 70 | 0.30 Score on a scale | Standard Deviation 0.42 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 49 | 1.00 Score on a scale | Standard Deviation 1.32 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 50 | 0.80 Score on a scale | Standard Deviation 0.91 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 57 | 0.67 Score on a scale | Standard Deviation 0.58 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 58 | 1.17 Score on a scale | Standard Deviation 1.04 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 59 | 1.00 Score on a scale | Standard Deviation 0.87 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 60 | 0.50 Score on a scale | Standard Deviation 1.41 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 61 | 1.00 Score on a scale | Standard Deviation 0.87 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 76 | 0.30 Score on a scale | Standard Deviation 0.42 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 62 | 0.83 Score on a scale | Standard Deviation 0.76 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 77 | 0.40 Score on a scale | Standard Deviation 0.57 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 78 | 0.30 Score on a scale | Standard Deviation 0.14 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 79 | 0.10 Score on a scale | Standard Deviation 0.14 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 80 | 0.50 Score on a scale | Standard Deviation 0.71 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 81 | 0.40 Score on a scale | Standard Deviation 0.57 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 86 | 0.40 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 66 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 67 | 1.00 Score on a scale | Standard Deviation 1.41 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 87 | 0.40 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 68 | 0.75 Score on a scale | Standard Deviation 1.06 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 69 | 0.50 Score on a scale | Standard Deviation 0.71 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 77 | 0.50 Score on a scale | Standard Deviation 0.71 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 78 | 1.00 Score on a scale | Standard Deviation 1.41 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 79 | 0.50 Score on a scale | Standard Deviation 0.71 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 80 | 0.75 Score on a scale | Standard Deviation 1.06 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 81 | 0.75 Score on a scale | Standard Deviation 1.06 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 82 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 87 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 1 | 0.13 Score on a scale | Standard Deviation 0.86 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 2 | -0.01 Score on a scale | Standard Deviation 0.99 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 3 | -0.03 Score on a scale | Standard Deviation 0.76 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 4 | -0.02 Score on a scale | Standard Deviation 1.02 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 10 | -0.07 Score on a scale | Standard Deviation 1.12 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 11 | 0.02 Score on a scale | Standard Deviation 1.24 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 12 | -0.08 Score on a scale | Standard Deviation 1.3 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 13 | -0.09 Score on a scale | Standard Deviation 1.22 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 14 | -0.20 Score on a scale | Standard Deviation 1.19 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 15 | -0.05 Score on a scale | Standard Deviation 1.35 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 16 | -0.10 Score on a scale | Standard Deviation 1.06 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 17 | -0.04 Score on a scale | Standard Deviation 0.99 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 18 | 0.02 Score on a scale | Standard Deviation 1.23 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 19 | -0.23 Score on a scale | Standard Deviation 1.29 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 20 | 0.00 Score on a scale | Standard Deviation 1.33 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 21 | -0.17 Score on a scale | Standard Deviation 1.4 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 22 | -0.20 Score on a scale | Standard Deviation 1.32 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 23 | -0.22 Score on a scale | Standard Deviation 1.18 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 24 | -0.13 Score on a scale | Standard Deviation 1.51 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 25 | -0.45 Score on a scale | Standard Deviation 0.96 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 26 | -0.46 Score on a scale | Standard Deviation 1.2 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 27 | -0.50 Score on a scale | Standard Deviation 1.22 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 28 | -0.45 Score on a scale | Standard Deviation 0.88 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 29 | -0.50 Score on a scale | Standard Deviation 1.31 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 30 | -0.88 Score on a scale | Standard Deviation 1.13 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 31 | -0.86 Score on a scale | Standard Deviation 1.4 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 32 | -0.73 Score on a scale | Standard Deviation 1.56 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 33 | -0.77 Score on a scale | Standard Deviation 1.13 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 34 | -0.80 Score on a scale | Standard Deviation 1.18 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 36 | -0.17 Score on a scale | Standard Deviation 0.66 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 37 | -0.25 Score on a scale | Standard Deviation 0.89 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 38 | 0.05 Score on a scale | Standard Deviation 0.88 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 39 | -0.50 Score on a scale | Standard Deviation 0.9 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 40 | -0.36 Score on a scale | Standard Deviation 0.94 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 41 | 0.21 Score on a scale | Standard Deviation 0.57 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 42 | 0.17 Score on a scale | Standard Deviation 0.52 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 43 | 0.10 Score on a scale | Standard Deviation 0.55 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 44 | 0.36 Score on a scale | Standard Deviation 0.94 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 45 | 0.25 Score on a scale | Standard Deviation 0.5 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 46 | 0.10 Score on a scale | Standard Deviation 0.96 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 47 | 0.50 Score on a scale | Standard Deviation 0.58 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 48 | 0.17 Score on a scale | Standard Deviation 0.29 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 49 | 0.67 Score on a scale | Standard Deviation 0.76 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 50 | 0.30 Score on a scale | Standard Deviation 0.76 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 51 | 0.13 Score on a scale | Standard Deviation 0.63 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 52 | 0.63 Score on a scale | Standard Deviation 0.95 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 53 | 0.70 Score on a scale | Standard Deviation 0.76 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 54 | 0.50 Score on a scale | Standard Deviation 0.41 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 55 | 0.67 Score on a scale | Standard Deviation 0.29 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 68 | 0.25 Score on a scale | Standard Deviation 0.35 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 69 | 0.25 Score on a scale | Standard Deviation 0.35 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 70 | 0.25 Score on a scale | Standard Deviation 0.35 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 71 | 0.00 Score on a scale | Standard Deviation 0 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 72 | -0.50 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 73 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 74 | 0.00 Score on a scale | Standard Deviation 0 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 75 | 0.00 Score on a scale | Standard Deviation 0.71 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 76 | 0.25 Score on a scale | Standard Deviation 0.35 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 77 | 0.00 Score on a scale | Standard Deviation 0 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 78 | 0.25 Score on a scale | Standard Deviation 0.35 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 79 | 0.00 Score on a scale | Standard Deviation 0 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 80 | 0.25 Score on a scale | Standard Deviation 0.35 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 1 | 0.42 Score on a scale | Standard Deviation 0.81 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 32 | 0.22 Score on a scale | Standard Deviation 1 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 70 | 1.00 Score on a scale | Standard Deviation 1.41 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 18 | 0.39 Score on a scale | Standard Deviation 0.65 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 71 | 0.50 Score on a scale | Standard Deviation 0.71 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 13 | 0.07 Score on a scale | Standard Deviation 1.17 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 72 | 1.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 7 | 0.63 Score on a scale | Standard Deviation 0.74 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 14 | 0.07 Score on a scale | Standard Deviation 1.16 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 19 | 0.29 Score on a scale | Standard Deviation 0.86 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 19 | 0.11 Score on a scale | Standard Deviation 1.01 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 48 | 0.60 Score on a scale | Standard Deviation 0.72 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 20 | 0.20 Score on a scale | Standard Deviation 1.32 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 73 | 1.50 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 20 | 0.60 Score on a scale | Standard Deviation 0.87 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 74 | 0.50 Score on a scale | Standard Deviation 0.71 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 21 | 0.03 Score on a scale | Standard Deviation 0.83 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 8 | 0.50 Score on a scale | Standard Deviation 0.64 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 75 | 0.75 Score on a scale | Standard Deviation 1.06 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 21 | 0.27 Score on a scale | Standard Deviation 0.69 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 76 | 0.50 Score on a scale | Standard Deviation 0.71 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 83 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 23 | 0.00 Score on a scale | Standard Deviation 1 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 24 | -0.09 Score on a scale | Standard Deviation 0.88 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 25 | 0.27 Score on a scale | Standard Deviation 0.79 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 84 | 0.50 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 26 | 0.12 Score on a scale | Standard Deviation 1.31 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 40 | 0.57 Score on a scale | Standard Deviation 0.76 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 85 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 42 | 0.30 Score on a scale | Standard Deviation 0.55 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 28 | 0.00 Score on a scale | Standard Deviation 0.81 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 86 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 29 | -0.25 Score on a scale | Standard Deviation 0.87 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 35 | 0.00 Score on a scale | Standard Deviation 1.16 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 2 | 0.33 Score on a scale | Standard Deviation 0.73 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 36 | 0.06 Score on a scale | Standard Deviation 0.85 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 22 | 0.55 Score on a scale | Standard Deviation 0.92 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 9 | 0.46 Score on a scale | Standard Deviation 0.86 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 37 | 0.31 Score on a scale | Standard Deviation 1.25 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 50 | 0.24 Score on a scale | Standard Deviation 0.59 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 23 | 0.34 Score on a scale | Standard Deviation 0.69 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 51 | 1.05 Score on a scale | Standard Deviation 1.02 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 34 | 0.40 Score on a scale | Standard Deviation 1.31 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 24 | 0.36 Score on a scale | Standard Deviation 1.02 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 60 | 1.20 Score on a scale | Standard Deviation 1.13 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 10 | 0.43 Score on a scale | Standard Deviation 0.8 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 61 | 0.73 Score on a scale | Standard Deviation 0.76 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 41 | 0.36 Score on a scale | Standard Deviation 1.07 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 25 | 0.22 Score on a scale | Standard Deviation 0.46 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 42 | 0.25 Score on a scale | Standard Deviation 1.04 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 3 | 0.25 Score on a scale | Standard Deviation 0.75 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 43 | 0.30 Score on a scale | Standard Deviation 1.15 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 26 | 0.32 Score on a scale | Standard Deviation 0.82 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 11 | 0.36 Score on a scale | Standard Deviation 0.77 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 44 | 0.14 Score on a scale | Standard Deviation 0.99 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 62 | 0.67 Score on a scale | Standard Deviation 0.83 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 27 | 0.35 Score on a scale | Standard Deviation 1.07 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 63 | 0.30 Score on a scale | Standard Deviation 0.42 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 5 | -0.01 Score on a scale | Standard Deviation 0.84 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 46 | 0.56 Score on a scale | Standard Deviation 0.71 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 6 | -0.18 Score on a scale | Standard Deviation 0.93 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 64 | 0.20 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 7 | -0.20 Score on a scale | Standard Deviation 0.92 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 28 | 0.35 Score on a scale | Standard Deviation 0.92 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 8 | -0.10 Score on a scale | Standard Deviation 0.9 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 65 | 0.60 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 9 | -0.24 Score on a scale | Standard Deviation 0.86 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 12 | 0.39 Score on a scale | Standard Deviation 0.82 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 56 | 0.50 Score on a scale | Standard Deviation 0.41 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 29 | 0.20 Score on a scale | Standard Deviation 0.89 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 57 | 0.50 Score on a scale | Standard Deviation 0.5 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 45 | 0.63 Score on a scale | Standard Deviation 0.48 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 58 | 0.67 Score on a scale | Standard Deviation 0.29 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 1 | 0.57 Score on a scale | Standard Deviation 1.23 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 59 | 0.33 Score on a scale | Standard Deviation 0.58 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 66 | 0.40 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 60 | 0.75 Score on a scale | Standard Deviation 0.35 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 51 | 0.88 Score on a scale | Standard Deviation 0.85 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 61 | 0.50 Score on a scale | Standard Deviation 0.5 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 71 | 0.10 Score on a scale | Standard Deviation 0.14 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 62 | 0.33 Score on a scale | Standard Deviation 0.58 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 4 | 0.43 Score on a scale | Standard Deviation 0.87 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 63 | 0.00 Score on a scale | Standard Deviation 0 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 72 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 64 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 13 | 0.43 Score on a scale | Standard Deviation 0.83 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 65 | 0.50 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 73 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 66 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 2 | 0.42 Score on a scale | Standard Deviation 1.13 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 67 | 0.25 Score on a scale | Standard Deviation 0.35 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 32 | 0.41 Score on a scale | Standard Deviation 1.61 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 52 | 0.75 Score on a scale | Standard Deviation 1.19 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 81 | 0.25 Score on a scale | Standard Deviation 0.35 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 30 | 0.18 Score on a scale | Standard Deviation 0.96 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 82 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 53 | 0.70 Score on a scale | Standard Deviation 0.84 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 83 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 74 | 0.20 Score on a scale | Standard Deviation 0.28 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 84 | 0.50 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 3 | 0.25 Score on a scale | Standard Deviation 1.26 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 85 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 14 | 0.26 Score on a scale | Standard Deviation 0.88 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 86 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 75 | 0.30 Score on a scale | Standard Deviation 0.42 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 87 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 54 | 1.13 Score on a scale | Standard Deviation 1.03 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 5 | 0.55 Score on a scale | Standard Deviation 0.81 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 55 | 1.17 Score on a scale | Standard Deviation 1.26 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 5 | 0.27 Score on a scale | Standard Deviation 1.19 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 56 | 0.38 Score on a scale | Standard Deviation 0.48 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 15 | 0.36 Score on a scale | Standard Deviation 1.07 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 45 | 0.65 Score on a scale | Standard Deviation 0.38 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 82 | 0.60 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 16 | 0.18 Score on a scale | Standard Deviation 0.82 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 31 | 0.18 Score on a scale | Standard Deviation 0.84 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 63 | 0.50 Score on a scale | Standard Deviation 0.71 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 7 | 0.23 Score on a scale | Standard Deviation 1.04 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 64 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 6 | 0.50 Score on a scale | Standard Deviation 0.68 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 83 | 0.60 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 65 | 0.00 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 8 | 0.17 Score on a scale | Standard Deviation 1.12 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 84 | 0.80 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 17 | 0.48 Score on a scale | Standard Deviation 0.87 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 85 | 0.60 Score on a scale | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 44 | 0.49 Score on a scale | Standard Deviation 0.6 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 105 | 1.00 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 106 | 0.50 Score on a scale | Standard Deviation 0.71 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 107 | 1.00 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 108 | 1.50 Score on a scale | Standard Deviation 0.71 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 109 | 1.75 Score on a scale | Standard Deviation 1.06 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 110 | 2.00 Score on a scale | Standard Deviation 1.41 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 111 | 1.50 Score on a scale | Standard Deviation 0.71 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 4 | -0.03 Score on a scale | Standard Deviation 0.98 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 5 | 0.00 Score on a scale | Standard Deviation 0.96 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 6 | -0.18 Score on a scale | Standard Deviation 0.89 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 7 | -0.06 Score on a scale | Standard Deviation 0.98 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 8 | -0.13 Score on a scale | Standard Deviation 0.91 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 55 | 0.12 Score on a scale | Standard Deviation 0.94 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 56 | 0.14 Score on a scale | Standard Deviation 0.97 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 57 | 0.15 Score on a scale | Standard Deviation 0.66 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 58 | 0.08 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 59 | 0.06 Score on a scale | Standard Deviation 0.63 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 60 | -0.04 Score on a scale | Standard Deviation 0.83 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 61 | 0.00 Score on a scale | Standard Deviation 0.88 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 62 | 0.14 Score on a scale | Standard Deviation 0.79 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 63 | -0.04 Score on a scale | Standard Deviation 0.86 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 64 | 0.35 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 65 | 0.12 Score on a scale | Standard Deviation 0.92 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 66 | 0.45 Score on a scale | Standard Deviation 1.21 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 67 | -0.09 Score on a scale | Standard Deviation 0.66 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 80 | 0.33 Score on a scale | Standard Deviation 0.9 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 81 | 0.58 Score on a scale | Standard Deviation 1.28 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 82 | 0.25 Score on a scale | Standard Deviation 1.08 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 83 | 0.67 Score on a scale | Standard Deviation 1.21 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 84 | 0.29 Score on a scale | Standard Deviation 0.95 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 85 | 0.38 Score on a scale | Standard Deviation 1.03 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 86 | 0.57 Score on a scale | Standard Deviation 1.24 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 87 | 0.64 Score on a scale | Standard Deviation 1.35 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 88 | 0.64 Score on a scale | Standard Deviation 1.14 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 89 | 0.50 Score on a scale | Standard Deviation 1.32 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 90 | 0.43 Score on a scale | Standard Deviation 1.1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 91 | 0.50 Score on a scale | Standard Deviation 1.19 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 92 | 0.67 Score on a scale | Standard Deviation 1.21 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 93 | 0.79 Score on a scale | Standard Deviation 1.38 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 94 | 0.30 Score on a scale | Standard Deviation 0.97 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 95 | 0.67 Score on a scale | Standard Deviation 1.25 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 117 | 0.50 Score on a scale | Standard Deviation 2.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 118 | 0.50 Score on a scale | Standard Deviation 2.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 119 | 0.50 Score on a scale | Standard Deviation 2.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 120 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 121 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 122 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 123 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 124 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 125 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 126 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 127 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 128 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 31 | 0.33 Score on a scale | Standard Deviation 0.9 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 32 | 0.35 Score on a scale | Standard Deviation 1.2 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 46 | 0.37 Score on a scale | Standard Deviation 0.97 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 47 | 0.39 Score on a scale | Standard Deviation 0.92 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 129 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 130 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 131 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 1 | 0.12 Score on a scale | Standard Deviation 0.76 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 2 | 0.29 Score on a scale | Standard Deviation 0.87 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 3 | 0.25 Score on a scale | Standard Deviation 0.97 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 4 | 0.28 Score on a scale | Standard Deviation 0.89 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 5 | 0.21 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 6 | 0.21 Score on a scale | Standard Deviation 0.95 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 7 | 0.32 Score on a scale | Standard Deviation 1.08 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 8 | 0.25 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 9 | 0.34 Score on a scale | Standard Deviation 1.01 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 10 | 0.49 Score on a scale | Standard Deviation 1.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 11 | 0.24 Score on a scale | Standard Deviation 0.97 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 12 | 0.35 Score on a scale | Standard Deviation 1.04 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 13 | 0.23 Score on a scale | Standard Deviation 0.94 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 14 | 0.26 Score on a scale | Standard Deviation 1.14 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 15 | 0.39 Score on a scale | Standard Deviation 1.22 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 16 | 0.26 Score on a scale | Standard Deviation 1.13 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 17 | 0.16 Score on a scale | Standard Deviation 1.17 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 18 | 0.21 Score on a scale | Standard Deviation 1.05 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 19 | 0.33 Score on a scale | Standard Deviation 1.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 20 | 0.23 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 21 | 0.40 Score on a scale | Standard Deviation 0.93 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 22 | 0.22 Score on a scale | Standard Deviation 0.99 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 23 | 0.38 Score on a scale | Standard Deviation 0.98 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 24 | 0.42 Score on a scale | Standard Deviation 1.06 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 25 | 0.50 Score on a scale | Standard Deviation 1.14 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 26 | 0.28 Score on a scale | Standard Deviation 0.95 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 27 | 0.37 Score on a scale | Standard Deviation 1.04 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 28 | 0.45 Score on a scale | Standard Deviation 0.83 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 29 | 0.38 Score on a scale | Standard Deviation 0.85 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 1 | 0.31 Score on a scale | Standard Deviation 0.84 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 2 | 0.33 Score on a scale | Standard Deviation 0.85 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 3 | 0.43 Score on a scale | Standard Deviation 0.97 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 4 | 0.43 Score on a scale | Standard Deviation 1.08 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 5 | 0.28 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 6 | 0.25 Score on a scale | Standard Deviation 0.85 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 30 | 0.54 Score on a scale | Standard Deviation 1.01 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 7 | 0.30 Score on a scale | Standard Deviation 0.97 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 8 | 0.20 Score on a scale | Standard Deviation 0.82 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 31 | 0.41 Score on a scale | Standard Deviation 0.86 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 32 | 0.58 Score on a scale | Standard Deviation 1.04 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 13 | 0.30 Score on a scale | Standard Deviation 1.04 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 35 | 0.27 Score on a scale | Standard Deviation 1.02 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 19 | 0.23 Score on a scale | Standard Deviation 0.94 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 20 | 0.23 Score on a scale | Standard Deviation 0.95 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 21 | 0.11 Score on a scale | Standard Deviation 0.87 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 22 | 0.19 Score on a scale | Standard Deviation 1.02 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 35 | 0.28 Score on a scale | Standard Deviation 1.13 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 36 | 0.08 Score on a scale | Standard Deviation 0.95 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 49 | 0.47 Score on a scale | Standard Deviation 0.76 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 50 | 0.53 Score on a scale | Standard Deviation 0.96 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 51 | 0.59 Score on a scale | Standard Deviation 1.02 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 59 | 0.18 Score on a scale | Standard Deviation 1.08 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 60 | 0.57 Score on a scale | Standard Deviation 0.89 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 41 | 0.30 Score on a scale | Standard Deviation 1.01 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 42 | 0.33 Score on a scale | Standard Deviation 1.05 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 61 | 0.54 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 43 | 0.18 Score on a scale | Standard Deviation 1.29 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 62 | 0.66 Score on a scale | Standard Deviation 1.11 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 63 | 0.77 Score on a scale | Standard Deviation 0.8 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 64 | 0.66 Score on a scale | Standard Deviation 1.07 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 44 | 0.42 Score on a scale | Standard Deviation 1.15 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 65 | 0.94 Score on a scale | Standard Deviation 1.28 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 45 | 0.31 Score on a scale | Standard Deviation 0.9 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 71 | 0.84 Score on a scale | Standard Deviation 1.19 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 72 | 0.80 Score on a scale | Standard Deviation 1.09 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 73 | 0.67 Score on a scale | Standard Deviation 1.11 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 51 | 0.31 Score on a scale | Standard Deviation 0.89 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 52 | 0.54 Score on a scale | Standard Deviation 1.11 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 74 | 0.89 Score on a scale | Standard Deviation 1.35 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 53 | 0.29 Score on a scale | Standard Deviation 1.08 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 54 | 0.25 Score on a scale | Standard Deviation 0.87 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 55 | 0.15 Score on a scale | Standard Deviation 0.99 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 56 | 0.29 Score on a scale | Standard Deviation 0.96 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 81 | 0.53 Score on a scale | Standard Deviation 1.53 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 82 | 0.53 Score on a scale | Standard Deviation 1.09 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 62 | 0.43 Score on a scale | Standard Deviation 1.16 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 63 | 0.29 Score on a scale | Standard Deviation 0.86 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 64 | 0.40 Score on a scale | Standard Deviation 1.22 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 83 | 0.87 Score on a scale | Standard Deviation 1.28 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 84 | 0.89 Score on a scale | Standard Deviation 1.13 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 85 | 0.83 Score on a scale | Standard Deviation 1.27 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 96 | 1.13 Score on a scale | Standard Deviation 1.24 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 70 | 0.18 Score on a scale | Standard Deviation 0.81 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 71 | 0.45 Score on a scale | Standard Deviation 1.32 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 97 | 1.26 Score on a scale | Standard Deviation 1.35 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 98 | 0.80 Score on a scale | Standard Deviation 1.19 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 99 | 0.70 Score on a scale | Standard Deviation 1.58 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 100 | 0.88 Score on a scale | Standard Deviation 1.38 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 101 | 1.13 Score on a scale | Standard Deviation 1.54 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 72 | 0.42 Score on a scale | Standard Deviation 1.18 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 73 | 0.27 Score on a scale | Standard Deviation 1.19 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 102 | 0.96 Score on a scale | Standard Deviation 1.58 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 74 | 0.50 Score on a scale | Standard Deviation 1.3 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 75 | 0.33 Score on a scale | Standard Deviation 1.32 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 111 | 1.60 Score on a scale | Standard Deviation 1.41 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 112 | 1.50 Score on a scale | Standard Deviation 1.56 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 83 | 0.50 Score on a scale | Standard Deviation 1.48 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 113 | 1.50 Score on a scale | Standard Deviation 1.56 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 84 | 0.43 Score on a scale | Standard Deviation 1.43 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 85 | 0.38 Score on a scale | Standard Deviation 1.41 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 114 | 1.60 Score on a scale | Standard Deviation 1.7 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 86 | 0.21 Score on a scale | Standard Deviation 1.44 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 115 | 1.40 Score on a scale | Standard Deviation 1.41 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 87 | 0.29 Score on a scale | Standard Deviation 1.41 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 119 | 1.50 Score on a scale | Standard Deviation 1.56 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 120 | 2.20 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 121 | 2.40 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 122 | 2.20 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 123 | 2.20 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 124 | 2.20 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 125 | 2.20 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 126 | 2.20 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 128 | 2.20 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 129 | 2.20 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 131 | 2.20 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 92 | 0.33 Score on a scale | Standard Deviation 1.54 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 97 | 0.50 Score on a scale | Standard Deviation 1.47 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 103 | 0.63 Score on a scale | Standard Deviation 1.11 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 104 | 1.00 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 89 | 0.56 Score on a scale | Standard Deviation 1.05 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 90 | 0.74 Score on a scale | Standard Deviation 1.38 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 91 | 0.51 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 92 | 0.87 Score on a scale | Standard Deviation 1.26 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 93 | 1.20 Score on a scale | Standard Deviation 1.39 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 94 | 0.48 Score on a scale | Standard Deviation 0.99 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 43 | 0.03 Score on a scale | Standard Deviation 1.06 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 95 | 0.87 Score on a scale | Standard Deviation 1.32 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 69 | 0.50 Score on a scale | Standard Deviation 1.33 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 103 | 0.55 Score on a scale | Standard Deviation 1.68 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 104 | 1.07 Score on a scale | Standard Deviation 1.33 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 105 | 1.07 Score on a scale | Standard Deviation 1.33 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 76 | 0.00 Score on a scale | Standard Deviation 0.93 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 78 | 0.36 Score on a scale | Standard Deviation 1.03 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 77 | 0.19 Score on a scale | Standard Deviation 1.33 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 44 | -0.11 Score on a scale | Standard Deviation 1.09 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 106 | 0.40 Score on a scale | Standard Deviation 0.28 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 78 | 0.21 Score on a scale | Standard Deviation 1.44 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 115 | 0.50 Score on a scale | Standard Deviation 2.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 107 | 1.13 Score on a scale | Standard Deviation 1.63 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 79 | 0.31 Score on a scale | Standard Deviation 1.31 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 108 | 1.50 Score on a scale | Standard Deviation 1.56 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 109 | 1.30 Score on a scale | Standard Deviation 1.27 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 45 | -0.26 Score on a scale | Standard Deviation 0.92 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 80 | 0.72 Score on a scale | Standard Deviation 1.7 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 79 | 0.63 Score on a scale | Standard Deviation 1.19 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 110 | 1.50 Score on a scale | Standard Deviation 1.56 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 81 | 0.08 Score on a scale | Standard Deviation 1.72 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 46 | 0.08 Score on a scale | Standard Deviation 0.85 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 82 | 0.08 Score on a scale | Standard Deviation 1.24 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 116 | 1.30 Score on a scale | Standard Deviation 1.27 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 116 | 0.50 Score on a scale | Standard Deviation 2.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 117 | 1.50 Score on a scale | Standard Deviation 1.56 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 88 | 0.43 Score on a scale | Standard Deviation 1.17 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 118 | 1.30 Score on a scale | Standard Deviation 1.27 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 127 | 2.20 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 130 | 2.20 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 89 | -0.20 Score on a scale | Standard Deviation 0.91 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 90 | 0.07 Score on a scale | Standard Deviation 1.13 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 91 | -0.07 Score on a scale | Standard Deviation 0.89 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 93 | 0.50 Score on a scale | Standard Deviation 1.47 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 94 | 0.20 Score on a scale | Standard Deviation 1.35 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 95 | 0.33 Score on a scale | Standard Deviation 1.54 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 96 | 0.33 Score on a scale | Standard Deviation 1.54 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 98 | 0.33 Score on a scale | Standard Deviation 1.54 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 99 | 0.88 Score on a scale | Standard Deviation 1.18 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 100 | 0.50 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 101 | 0.83 Score on a scale | Standard Deviation 0.93 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 102 | 0.50 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 112 | 1.50 Score on a scale | Standard Deviation 0.71 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 113 | 1.50 Score on a scale | Standard Deviation 0.71 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 114 | 2.00 Score on a scale | Standard Deviation 1.41 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 115 | 1.75 Score on a scale | Standard Deviation 1.06 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 116 | 2.00 Score on a scale | Standard Deviation 1.41 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 117 | 2.00 Score on a scale | Standard Deviation 1.41 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 118 | 2.00 Score on a scale | Standard Deviation 1.41 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 119 | 1.75 Score on a scale | Standard Deviation 1.06 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 120 | 2.50 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 121 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 122 | 3.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 123 | 2.50 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 124 | 3.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 125 | 3.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 126 | 3.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 127 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 128 | 3.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 129 | 3.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 130 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 131 | 2.00 Score on a scale | — |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 47 | -0.03 Score on a scale | Standard Deviation 0.9 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 1 | 0.10 Score on a scale | Standard Deviation 0.7 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 96 | 0.58 Score on a scale | Standard Deviation 1.2 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 2 | 0.19 Score on a scale | Standard Deviation 0.75 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 48 | 0.23 Score on a scale | Standard Deviation 0.68 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 3 | -0.01 Score on a scale | Standard Deviation 0.76 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 97 | 0.57 Score on a scale | Standard Deviation 1.13 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 9 | -0.06 Score on a scale | Standard Deviation 1.01 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 49 | 0.26 Score on a scale | Standard Deviation 0.85 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 10 | -0.10 Score on a scale | Standard Deviation 1.02 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 98 | 0.67 Score on a scale | Standard Deviation 1.25 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 11 | -0.07 Score on a scale | Standard Deviation 1.07 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 42 | 0.52 Score on a scale | Standard Deviation 1.07 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 50 | 0.00 Score on a scale | Standard Deviation 0.85 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 43 | 0.41 Score on a scale | Standard Deviation 1.18 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 44 | 0.31 Score on a scale | Standard Deviation 1.14 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 12 | -0.09 Score on a scale | Standard Deviation 0.97 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 45 | 0.53 Score on a scale | Standard Deviation 1.04 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 99 | 0.25 Score on a scale | Standard Deviation 0.96 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 33 | 0.04 Score on a scale | Standard Deviation 1.03 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 13 | -0.20 Score on a scale | Standard Deviation 0.93 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 48 | 0.39 Score on a scale | Standard Deviation 0.93 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 51 | 0.06 Score on a scale | Standard Deviation 0.93 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 34 | 0.31 Score on a scale | Standard Deviation 0.98 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 14 | -0.07 Score on a scale | Standard Deviation 0.95 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 100 | 0.60 Score on a scale | Standard Deviation 1.14 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 15 | -0.19 Score on a scale | Standard Deviation 1.04 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 9 | 0.33 Score on a scale | Standard Deviation 1.07 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 52 | 0.27 Score on a scale | Standard Deviation 0.97 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 10 | 0.25 Score on a scale | Standard Deviation 1.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 16 | -0.19 Score on a scale | Standard Deviation 0.94 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 11 | 0.21 Score on a scale | Standard Deviation 0.96 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 101 | 0.50 Score on a scale | Standard Deviation 1.05 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 17 | -0.21 Score on a scale | Standard Deviation 1.09 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 33 | 0.36 Score on a scale | Standard Deviation 0.96 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 53 | 0.38 Score on a scale | Standard Deviation 0.71 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 34 | 0.28 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 18 | -0.26 Score on a scale | Standard Deviation 0.93 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 12 | 0.33 Score on a scale | Standard Deviation 0.97 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 14 | 0.27 Score on a scale | Standard Deviation 0.85 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 102 | 0.50 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 19 | -0.27 Score on a scale | Standard Deviation 0.87 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 15 | 0.45 Score on a scale | Standard Deviation 1.01 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 36 | -0.02 Score on a scale | Standard Deviation 1.04 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 54 | 0.07 Score on a scale | Standard Deviation 0.7 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 20 | -0.33 Score on a scale | Standard Deviation 0.95 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 37 | 0.42 Score on a scale | Standard Deviation 1.13 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 103 | 0.25 Score on a scale | Standard Deviation 0.96 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 16 | 0.19 Score on a scale | Standard Deviation 0.99 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 38 | 0.50 Score on a scale | Standard Deviation 1.25 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 21 | -0.19 Score on a scale | Standard Deviation 0.88 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 104 | 0.00 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 39 | 0.25 Score on a scale | Standard Deviation 0.86 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 17 | 0.22 Score on a scale | Standard Deviation 1.2 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 22 | -0.17 Score on a scale | Standard Deviation 0.89 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 18 | 0.26 Score on a scale | Standard Deviation 0.85 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 68 | 0.61 Score on a scale | Standard Deviation 1.29 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 23 | 0.33 Score on a scale | Standard Deviation 0.84 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 24 | 0.18 Score on a scale | Standard Deviation 1.13 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 25 | 0.29 Score on a scale | Standard Deviation 0.87 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 26 | 0.11 Score on a scale | Standard Deviation 0.72 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 40 | 0.44 Score on a scale | Standard Deviation 1.13 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 23 | 0.05 Score on a scale | Standard Deviation 0.9 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 105 | 0.33 Score on a scale | Standard Deviation 1.53 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 41 | 0.53 Score on a scale | Standard Deviation 1.17 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 27 | 0.20 Score on a scale | Standard Deviation 0.8 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 28 | 0.23 Score on a scale | Standard Deviation 0.98 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 29 | 0.18 Score on a scale | Standard Deviation 0.8 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 24 | -0.12 Score on a scale | Standard Deviation 0.8 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 69 | 0.50 Score on a scale | Standard Deviation 1.18 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 52 | 0.72 Score on a scale | Standard Deviation 1.2 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 25 | 0.14 Score on a scale | Standard Deviation 0.82 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 53 | 0.40 Score on a scale | Standard Deviation 1.01 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 106 | -0.50 Score on a scale | Standard Deviation 0.71 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 54 | 0.63 Score on a scale | Standard Deviation 1.02 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 26 | -0.03 Score on a scale | Standard Deviation 0.89 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 55 | 0.72 Score on a scale | Standard Deviation 1.13 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 70 | 0.23 Score on a scale | Standard Deviation 0.79 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 56 | 0.61 Score on a scale | Standard Deviation 1.07 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 27 | -0.05 Score on a scale | Standard Deviation 0.94 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 57 | 0.45 Score on a scale | Standard Deviation 1.02 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 37 | 0.39 Score on a scale | Standard Deviation 0.89 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 107 | 0.00 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 28 | 0.08 Score on a scale | Standard Deviation 0.84 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 38 | 0.31 Score on a scale | Standard Deviation 1.2 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 71 | 0.55 Score on a scale | Standard Deviation 0.9 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 39 | 0.14 Score on a scale | Standard Deviation 0.92 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 29 | 0.05 Score on a scale | Standard Deviation 0.67 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 40 | 0.30 Score on a scale | Standard Deviation 1.21 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 58 | 0.60 Score on a scale | Standard Deviation 1.2 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 108 | 0.00 Score on a scale | Standard Deviation 1.41 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 30 | 0.12 Score on a scale | Standard Deviation 0.88 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 66 | 0.67 Score on a scale | Standard Deviation 1.31 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 46 | 0.37 Score on a scale | Standard Deviation 0.93 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 72 | 0.42 Score on a scale | Standard Deviation 0.93 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 31 | 0.05 Score on a scale | Standard Deviation 0.74 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 47 | 0.31 Score on a scale | Standard Deviation 0.86 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 67 | 0.33 Score on a scale | Standard Deviation 0.87 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 109 | 0.50 Score on a scale | Standard Deviation 2.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 68 | 0.82 Score on a scale | Standard Deviation 1.56 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 32 | -0.04 Score on a scale | Standard Deviation 1.04 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 69 | 0.74 Score on a scale | Standard Deviation 1.11 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 73 | 0.64 Score on a scale | Standard Deviation 1.07 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 33 | -0.29 Score on a scale | Standard Deviation 1.06 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 48 | 0.17 Score on a scale | Standard Deviation 0.79 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 70 | 0.75 Score on a scale | Standard Deviation 1.16 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 110 | 0.50 Score on a scale | Standard Deviation 2.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 49 | 0.47 Score on a scale | Standard Deviation 1.07 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 34 | -0.02 Score on a scale | Standard Deviation 0.75 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 50 | 0.20 Score on a scale | Standard Deviation 0.92 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 30 | 0.32 Score on a scale | Standard Deviation 0.95 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 57 | 0.08 Score on a scale | Standard Deviation 0.73 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 35 | -0.09 Score on a scale | Standard Deviation 1.1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 58 | 0.19 Score on a scale | Standard Deviation 1.07 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 74 | 0.56 Score on a scale | Standard Deviation 1.04 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 59 | 0.00 Score on a scale | Standard Deviation 0.87 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 36 | -0.36 Score on a scale | Standard Deviation 1.16 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 60 | 0.38 Score on a scale | Standard Deviation 1.08 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 75 | 0.71 Score on a scale | Standard Deviation 1.31 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 111 | 0.50 Score on a scale | Standard Deviation 2.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 37 | -0.04 Score on a scale | Standard Deviation 0.84 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 61 | 0.36 Score on a scale | Standard Deviation 1.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 75 | 0.67 Score on a scale | Standard Deviation 1.35 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 76 | 0.53 Score on a scale | Standard Deviation 1.05 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 38 | -0.07 Score on a scale | Standard Deviation 1.11 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 77 | 0.65 Score on a scale | Standard Deviation 1.55 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 112 | 0.00 Score on a scale | Standard Deviation 1.41 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 78 | 0.40 Score on a scale | Standard Deviation 1.11 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 39 | -0.20 Score on a scale | Standard Deviation 0.97 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 79 | 0.55 Score on a scale | Standard Deviation 1.25 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 76 | 0.31 Score on a scale | Standard Deviation 1 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 80 | 0.69 Score on a scale | Standard Deviation 1.43 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 40 | -0.39 Score on a scale | Standard Deviation 1.23 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 65 | 0.35 Score on a scale | Standard Deviation 1.11 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 113 | 0.50 Score on a scale | Standard Deviation 2.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 41 | 0.05 Score on a scale | Standard Deviation 0.84 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 66 | 0.45 Score on a scale | Standard Deviation 1.44 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 86 | 0.66 Score on a scale | Standard Deviation 1.33 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 77 | 0.56 Score on a scale | Standard Deviation 1.15 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 42 | -0.20 Score on a scale | Standard Deviation 1.16 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 67 | -0.09 Score on a scale | Standard Deviation 0.8 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 87 | 0.66 Score on a scale | Standard Deviation 1.23 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Cough, Week 114 | 0.50 Score on a scale | Standard Deviation 2.12 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnoea, Week 88 | 1.20 Score on a scale | Standard Deviation 1.43 |
| Atezolizumab | Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations | Chest Pain, Week 68 | 0.39 Score on a scale | Standard Deviation 1.45 |
Secondary
Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first.
Time frame: From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months)
Population: Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC2/3 or IC2/3-WT Population | 5.8 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC1/2/3 or IC1/2/3-WT Population | 5.7 Months |
| Atezolizumab | Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC2/3 or IC2/3-WT Population | 38.9 Months |
| Atezolizumab | Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC1/2/3 or IC1/2/3-WT Population | 26.3 Months |
Comparison: TC2/3 or IC2/3-WT Population95% CI: [0.135, 0.409]
Comparison: TC1/2/3 or IC1/2/3-WT Population95% CI: [0.19, 0.424]
Secondary
Duration of Response (DOR) in the TC3 or IC3-WT Populations
DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first.
Time frame: From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Duration of Response (DOR) in the TC3 or IC3-WT Populations | 6.7 Months |
| Atezolizumab | Duration of Response (DOR) in the TC3 or IC3-WT Populations | NA Months |
Comparison: TC3 or IC3-WT Population95% CI: [0.166, 0.8]
Secondary
Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1
PFS according to RECIST v1.1 in the bTMB subpopulations.
Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for participants with bTMB \>=10 Intent-to-treat Wild Type Population.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1 | bTMB >=10-WT Population | 4.3 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1 | bTMB >=16-WT Population | 4.4 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1 | bTMB >=20-WT Population | 5.2 Months |
| Atezolizumab | Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1 | bTMB >=10-WT Population | 5.5 Months |
| Atezolizumab | Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1 | bTMB >=16-WT Population | 6.8 Months |
| Atezolizumab | Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1 | bTMB >=20-WT Population | 6.8 Months |
Comparison: bTMB \>=10-WT Population95% CI: [0.525, 1.052]
Comparison: bTMB \>=16-WT Population95% CI: [0.331, 0.924]
Comparison: bTMB \>=20-WT Population95% CI: [0.295, 1.062]
Secondary
Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1
Investigator-assessed PFS according to RECIST v1.1 in the PD-L1 (defined with SP263 IHC assay)
Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for participants with PD-L1 Expression of PD-L1 status by SP263 \>=50%, SP263 \>=25%, SP263 \>=1% in the Intent-to-Treat Wild Type Population.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1 | SP263 >=50%-WT Population | 4.9 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1 | SP263 >=25%-WT Population | 4.9 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1 | SP263 >=1%-WT Population | 5.4 Months |
| Atezolizumab | Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1 | SP263 >=50%-WT Population | 7.0 Months |
| Atezolizumab | Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1 | SP263 >=25%-WT Population | 6.9 Months |
| Atezolizumab | Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1 | SP263 >=1%-WT Population | 6.8 Months |
Comparison: SP263 \>=50%-WT Population95% CI: [0.511, 0.89]
Comparison: SP263 \>=25%-WT Population95% CI: [0.539, 0.904]
Comparison: SP263 \>=1%-WT Population95% CI: [0.577, 0.91]
Secondary
Maximum Observed Serum Concentration (Cmax) of Atezolizumab
Time frame: 0 hour (predose) and 30 minutes after atezolizumab infusion on Day 1 (infusion duration = up to 1 hour)
Population: PK analyses was based on PK observations from all randomized participants who received atezolizumab and provided at least one PK sample that was evaluable.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Maximum Observed Serum Concentration (Cmax) of Atezolizumab | 411 micrograms per milliliter (μg/ mL) | Standard Deviation 163 |
Secondary
Minimum Observed Serum Concentration (Cmin) of Atezolizumab
Time frame: Prior to infusion (0 hour) on Day 1 of Cycles 2, 3, 4, 8, 16, and every eighth cycle thereafter, and at treatment discontinuation until data cut-off on 10 September 2018 (up to approximately 38 months) (cycle duration = 21 days)
Population: PK analyses was based on PK observations from all randomized participants who received atezolizumab and provided at least one PK sample that was evaluable.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab | Cycle 2 Day 1 | 76.7 micrograms per milliliter (μg/ mL) | Standard Deviation 57.6 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab | Cycle 3 Day 1 | 121 micrograms per milliliter (μg/ mL) | Standard Deviation 57.7 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab | Cycle 4 Day 1 | 154 micrograms per milliliter (μg/ mL) | Standard Deviation 90.1 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab | Cycle 8 Day 1 | 201 micrograms per milliliter (μg/ mL) | Standard Deviation 98.6 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab | Cycle 16 Day 1 | 213 micrograms per milliliter (μg/ mL) | Standard Deviation 102 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab | Cycle 24 Day 1 | 245 micrograms per milliliter (μg/ mL) | Standard Deviation 128 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab | Cycle 32 Day 1 | 276 micrograms per milliliter (μg/ mL) | Standard Deviation 110 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab | Cycle 40 Day 1 | 252 micrograms per milliliter (μg/ mL) | Standard Deviation 160 |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab | Cycle 48 Day 1 | 555 micrograms per milliliter (μg/ mL) | — |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Minimum Observed Serum Concentration (Cmin) of Atezolizumab | Treatment Discontinuation Visit | 121 micrograms per milliliter (μg/ mL) | Standard Deviation 88.8 |
Secondary
OS in Participants With Blood Tumor Mutational Burden (bTMB)
OS is defined as the time from randomization to death from any cause.
Time frame: From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for the bTMB subpopulations in the Intent-to-Treat Wild Type population.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | OS in Participants With Blood Tumor Mutational Burden (bTMB) | bTMB >=10-WT Population | 10.3 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | OS in Participants With Blood Tumor Mutational Burden (bTMB) | bTMB >=16-WT Population | 8.5 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | OS in Participants With Blood Tumor Mutational Burden (bTMB) | bTMB >=20-WT Population | 10.5 Months |
| Atezolizumab | OS in Participants With Blood Tumor Mutational Burden (bTMB) | bTMB >=10-WT Population | 11.2 Months |
| Atezolizumab | OS in Participants With Blood Tumor Mutational Burden (bTMB) | bTMB >=16-WT Population | 13.9 Months |
| Atezolizumab | OS in Participants With Blood Tumor Mutational Burden (bTMB) | bTMB >=20-WT Population | 17.2 Months |
Comparison: bTMB \>=10-WT Population95% CI: [0.578, 1.301]
Comparison: bTMB \>=16-WT Population95% CI: [0.414, 1.351]
Comparison: bTMB \>=20-WT Population95% CI: [0.362, 1.638]
Secondary
OS in Participants With PD-L1 Expression
OS is defined as the time from randomization to death from any cause.
Time frame: From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for participants with PD-L1 Expression of PD-L1 status by SP263 \>=50%, SP263 \>=25%, SP263 \>=1% in the Intent-to-Treat Wild Type Population.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | OS in Participants With PD-L1 Expression | SP263 >=50%-WT Population | 16.1 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | OS in Participants With PD-L1 Expression | SP263 >=25%-WT Population | 12.6 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | OS in Participants With PD-L1 Expression | SP263 =1%-WT Population | 14.0 Months |
| Atezolizumab | OS in Participants With PD-L1 Expression | SP263 >=50%-WT Population | 19.5 Months |
| Atezolizumab | OS in Participants With PD-L1 Expression | SP263 >=25%-WT Population | 18.2 Months |
| Atezolizumab | OS in Participants With PD-L1 Expression | SP263 =1%-WT Population | 17.8 Months |
Comparison: SP263 \>=50%-WT Population95% CI: [0.5, 1]
Comparison: SP263 \>=25%-WT Population95% CI: [0.502, 0.956]
Comparison: SP263 \>=1%-WT Population95% CI: [0.579, 1.018]
Secondary
Percentage of Participants Who Are Alive at 1 Year in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
Time frame: Baseline to 1 year or death, whichever occurs first until clinical cut-off date on 4 February 2020 (up to approximately 54.5 months)
Population: Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants Who Are Alive at 1 Year in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | 1-Year TC2/3 or IC2/3-WT Population | 58.65 Percentage of participants |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants Who Are Alive at 1 Year in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | 1-Year TC1/2/3 or IC1/2/3-WT Population | 54.89 Percentage of participants |
| Atezolizumab | Percentage of Participants Who Are Alive at 1 Year in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | 1-Year TC2/3 or IC2/3-WT Population | 63.39 Percentage of participants |
| Atezolizumab | Percentage of Participants Who Are Alive at 1 Year in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | 1-Year TC1/2/3 or IC1/2/3-WT Population | 59.95 Percentage of participants |
Comparison: 1-Year TC2/3 or IC2/3-WT Population95% CI: [-5.93, 15.4]
Comparison: 1-Year TC1/2/3 or IC1/2/3-WT Population95% CI: [-3.27, 13.4]
Secondary
Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations
Time frame: Baseline to 1 year or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations | 50.64 Percentage of participants |
| Atezolizumab | Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations | 64.90 Percentage of participants |
Comparison: 1-Year TC3 or IC3-WT Population95% CI: [-0.03, 28.55]
Secondary
Percentage of Participants Who Are Alive at 2 Years in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
Time frame: Baseline to 2 years or death, whichever occurs first until clinical cut-off date on 4 February 2020 (up to approximately 54.5 months)
Population: Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants Who Are Alive at 2 Years in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | 2-Years TC2/3 or IC2/3-WT Population | 35.42 Percentage of participants |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants Who Are Alive at 2 Years in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | 2-Years TC1/2/3 or IC1/2/3-WT Population | 30.82 Percentage of participants |
| Atezolizumab | Percentage of Participants Who Are Alive at 2 Years in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | 2-Years TC2/3 or IC2/3-WT Population | 44.15 Percentage of participants |
| Atezolizumab | Percentage of Participants Who Are Alive at 2 Years in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | 2-Years TC1/2/3 or IC1/2/3-WT Population | 41.76 Percentage of participants |
Comparison: 2-Years TC2/3 or IC2/3-WT Population95% CI: [-1.99, 19.45]
Comparison: 2-Years TC1/2/3 or IC1/2/3-WT Population95% CI: [2.83, 19.04]
Secondary
Percentage of Participants Who Are Alive at 2 Years in the TC3 or IC3-WT Populations
Time frame: Baseline to 2 years or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants Who Are Alive at 2 Years in the TC3 or IC3-WT Populations | 24.79 Percentage of participants |
| Atezolizumab | Percentage of Participants Who Are Alive at 2 Years in the TC3 or IC3-WT Populations | 45.49 Percentage of participants |
Comparison: 2-Years TC3 or IC3-WT Population95% CI: [2.94, 38.47]
Secondary
Percentage of Participants With Anti-therapeutic Antibodies (ATAs)
Time frame: Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: The baseline ADA-evaluable population included participants who had a baseline ADA result and had received at least one dose of atezolizumab. The post-baseline ADA evaluable population included participants who had at least one post-baseline ADA result and had received at least one dose of atezolizumab.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants With Anti-therapeutic Antibodies (ATAs) | Baseline evaluable participants | 1.4 Percentage of participants |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants With Anti-therapeutic Antibodies (ATAs) | Post-baseline evaluable participants | 24.3 Percentage of participants |
Secondary
Percentage of Participants With at Least One Adverse Event
Percentage of participants with at least one adverse event.
Time frame: Baseline up to until data cut-off on 8 March 2022 (up to approximately 79.5 months)
Population: Safety analyses included treated participants, defined as randomized participants who received any amount of study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants With at Least One Adverse Event | 95.1 Percentage of participants |
| Atezolizumab | Percentage of Participants With at Least One Adverse Event | 92.3 Percentage of participants |
Secondary
Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1.
Time frame: Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 4 Feb 2020 (up to approximately 54.5 months)
Population: Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC1/2/3 or IC1/2/3-WT Population | 32.1 Percentage of participants |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC2/3 or IC2/3-WT Population | 32.1 Percentage of participants |
| Atezolizumab | Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC2/3 or IC2/3-WT Population | 33.7 Percentage of participants |
| Atezolizumab | Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC1/2/3 or IC1/2/3-WT Population | 31.4 Percentage of participants |
Comparison: TC2/3 or IC2/3-WT Population95% CI: [-9.14, 12.42]
Comparison: TC1/2/3 or IC1/2/3-WT Population95% CI: [-8.84, 7.39]
Secondary
Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations
Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1.
Time frame: Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 10 Sep 2018 (up to approximately 38 months)
Population: Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations | 28.6 Percentage of participants |
| Atezolizumab | Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations | 38.3 Percentage of participants |
Comparison: TC3 or IC3-WT Population95% CI: [-4.07, 23.56]
Secondary
Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested.
Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months)
Population: Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC2/3 or IC2/3-WT Population | 5.5 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC1/2/3 or IC1/2/3-WT Population | 5.6 Months |
| Atezolizumab | Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC2/3 or IC2/3-WT Population | 7.3 Months |
| Atezolizumab | Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | TC1/2/3 or IC1/2/3-WT Population | 5.8 Months |
Comparison: TC2/3 or IC2/3-WT Populationp-value: 0.000495% CI: [0.501, 0.82]Log Rank
Comparison: TC1/2/3 or IC1/2/3-WT Populationp-value: 0.000495% CI: [0.595, 0.863]Log Rank
Secondary
Progression-free Survival (PFS) in the TC3 or IC3-WT Populations
PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested.
Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Progression-free Survival (PFS) in the TC3 or IC3-WT Populations | 5.0 Months |
| Atezolizumab | Progression-free Survival (PFS) in the TC3 or IC3-WT Populations | 8.1 Months |
Comparison: TC3 or IC3-WT Populationp-value: 0.00795% CI: [0.449, 0.884]Log Rank
Secondary
Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations
TTD in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant.
Time frame: Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for the TC3 or IC3-WT Populations.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations | Cough | 3.4 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnea | 1.0 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations | Chest pain | 1.1 Months |
| Atezolizumab | Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations | Cough | 3.5 Months |
| Atezolizumab | Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations | Dyspnea | 1.3 Months |
| Atezolizumab | Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations | Chest pain | 1.7 Months |
Comparison: Cough in TC3 or IC3-WT Populations95% CI: [0.657, 1.984]
Comparison: Dyspnoea in TC3 or IC3-WT Populations95% CI: [0.555, 1.43]
Comparison: Chest pain in TC3 or IC3-WT Populations95% CI: [0.737, 2.049]
Secondary
TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations
TTD in patient-reported lung cancer symptoms, defined as time from randomization to deterioration (10-point change) in any of the following symptom subscales (cough, dyspnea \[multi-item scale\], and chest pain), whichever occurs first, as measured by the EORTC QLQ-LC13. EORTC QLQ-LC13 module incorporates one multi-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis.
Time frame: Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)
Population: Analysis was performed for the TC3 or IC3-WT Populations.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations | Cough | NA Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations | Dyspnea | 11.8 Months |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations | Chest pain | NA Months |
| Atezolizumab | TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations | Cough | NA Months |
| Atezolizumab | TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations | Dyspnea | 11.1 Months |
| Atezolizumab | TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations | Chest pain | NA Months |
Comparison: Cough for TC3 or IC3-WT Populations95% CI: [0.477, 2.03]
Comparison: Dyspnea for TC3 or IC3-WT Populations95% CI: [0.569, 1.604]
Comparison: Chest pain for TC3 or IC3-WT Populations95% CI: [0.472, 2.222]